{"disease":{"id":"inhibitors","name":"inhibitors"},"drugs":{"marketed":[{"drug_id":"fitusiran","indication_name":"Factor IX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qfitlia","generic_name":"FITUSIRAN","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Antithrombin-directed RNA Interaction [EPC]","quality_score":10,"revenue":"400","mechanism":"Qfitlia works by using small RNA molecules to block the production of antithrombin, a protein that can interfere with blood clotting."},{"drug_id":"fitusiran","indication_name":"Factor VIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qfitlia","generic_name":"FITUSIRAN","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Antithrombin-directed RNA Interaction [EPC]","quality_score":10,"revenue":"400","mechanism":"Qfitlia works by using small RNA molecules to block the production of antithrombin, a protein that can interfere with blood clotting."},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia B (congenital factor IX deficiency) without factor IX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"gbt021601","indication_name":"Treatment of adult patients with severe hemophilia A with inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gbt021601","generic_name":"gbt021601","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"pf-07202954-single-dose","indication_name":"Hemophilia A with inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07202954 Single Dose","generic_name":"pf-07202954-single-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"concizumab","indication_name":"hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."},{"drug_id":"concizumab","indication_name":"hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."},{"drug_id":"pralidoxime","indication_name":"Cholinesterase Inhibitors Toxicity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pralidoxime Chloride (Autoinjector)","generic_name":"PRALIDOXIME","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Cholinesterase Reactivator","quality_score":75,"revenue":null,"mechanism":"Pralidoxime Chloride works by reactivating the enzyme acetylcholinesterase, which is inhibited by organophosphate poisoning."},{"drug_id":"hyoscyamine","indication_name":"Cholinesterase Inhibitors Toxicity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(-)-Atropine","generic_name":"Hyoscyamine","company_name":"University of Kansas Medical Center","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"hyoscyamine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."}],"pipeline":[{"drug_id":"phytonadione","indication_name":"Skin toxicity from EGFR inhibitors","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":10,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT04322786","title":"The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?","phase":"","overall_status":"UNKNOWN","enrollment_count":1302508,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT03719170","title":"Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program","phase":"NA","overall_status":"COMPLETED","enrollment_count":220306,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT07093684","title":"Dementia and Kidney Disease: Epidemiological Approaches to Risk Factors and Treatment Strategies","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03785509","title":"The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients","phase":"","overall_status":"COMPLETED","enrollment_count":47291,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT04255823","title":"Efficacy of a Multi-faceted Intervention to Deprescribe Proton Pump Inhibitors (PPI) in Primary Care: a Population-based, Pragmatic, Cluster-randomized Controlled Trial.","phase":"NA","overall_status":"COMPLETED","enrollment_count":34000,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04513834","title":"Efficacy of a Multi-faceted Intervention Combining an Educational Outreach Visit to General Practitioners and Patient Education Material to Deprescribe Proton Pump Inhibitors (PPI): a Population-based, Pragmatic, Cluster-randomized Controlled Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":25000,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06561243","title":"Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT07283965","title":"Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT03231059","title":"GLOBAL LEADERS Adjudication Sub-Study","phase":"","overall_status":"COMPLETED","enrollment_count":7365,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT03896139","title":"Identification of PAthways of Kinase Inhibitors TOxicity","phase":"","overall_status":"COMPLETED","enrollment_count":4000,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT06491953","title":"SGLT2-inhibitors on PC-AKI","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3600,"lead_sponsor_name":"Shenyang Northern Hospital","has_results":false},{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05306951","title":"Correct Timing of Head Imaging in Trauma","phase":"","overall_status":"UNKNOWN","enrollment_count":3200,"lead_sponsor_name":"University of Padova","has_results":false},{"nct_id":"NCT03462498","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3008,"lead_sponsor_name":"Kyoto University, Graduate School of Medicine","has_results":false},{"nct_id":"NCT04367883","title":"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Consorci Sanitari de Terrassa","has_results":false},{"nct_id":"NCT04806633","title":"Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":1722,"lead_sponsor_name":"G.Gennimatas General Hospital","has_results":false},{"nct_id":"NCT04999293","title":"Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention","phase":"","overall_status":"COMPLETED","enrollment_count":1505,"lead_sponsor_name":"The First Affiliated Hospital of Dalian Medical University","has_results":false},{"nct_id":"NCT06975384","title":"The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1270,"lead_sponsor_name":"Second Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT01322620","title":"Survey Evaluating the Psychosocial Effects of Living With Haemophilia","phase":"","overall_status":"COMPLETED","enrollment_count":1236,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03454646","title":"Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":1205,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT05628077","title":"Prevalence and Risk Factors for Pain and Related Adverse Reactions Among Breast Cancer Survivors on Aromatase Inhibitors","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05467358","title":"The Effect of Using Preendoscopic Proton Pump Inhibitors in Upper Gastrointestinal System Bleeding on Patient Prognosis","phase":"","overall_status":"COMPLETED","enrollment_count":1100,"lead_sponsor_name":"Ankara City Hospital Bilkent","has_results":false},{"nct_id":"NCT06423365","title":"A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":816,"lead_sponsor_name":"University of Utah","has_results":false},{"nct_id":"NCT05477979","title":"The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Second Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT07141056","title":"The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Guilin Medical University, China","has_results":false},{"nct_id":"NCT05582174","title":"PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":594,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06535568","title":"Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","phase":"NA","overall_status":"RECRUITING","enrollment_count":576,"lead_sponsor_name":"Fondazione Ricerca e Innovazione Cardiovascolare ETS","has_results":false},{"nct_id":"NCT04832672","title":"Sequence of Radiation and Targeted Therapy in Brain Metastases","phase":"","overall_status":"COMPLETED","enrollment_count":570,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05344963","title":"Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors","phase":"","overall_status":"COMPLETED","enrollment_count":503,"lead_sponsor_name":"Matteo Cameli","has_results":false},{"nct_id":"NCT05685238","title":"A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":451,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03948724","title":"Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology","phase":"NA","overall_status":"COMPLETED","enrollment_count":411,"lead_sponsor_name":"Institut Cancerologie de l'Ouest","has_results":false},{"nct_id":"NCT07034326","title":"Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":405,"lead_sponsor_name":"Kong Fanming","has_results":false},{"nct_id":"NCT03414840","title":"Assessment of Change in Atherosclerotic Plaque by Serial CCTA","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT06129474","title":"Deprescribing Inappropriate Proton Pump Inhibitors","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"University of Bern","has_results":false},{"nct_id":"NCT04780438","title":"Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":350,"lead_sponsor_name":"G.Gennimatas General Hospital","has_results":false},{"nct_id":"NCT07449065","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","phase":"","overall_status":"COMPLETED","enrollment_count":324,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT01579955","title":"Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":321,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03288441","title":"Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT06033287","title":"Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Hunan Cancer Hospital","has_results":false},{"nct_id":"NCT07409298","title":"Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":300,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT05053139","title":"A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":281,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03599284","title":"The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":279,"lead_sponsor_name":"Jiangsu vcare pharmaceutical technology co., LTD","has_results":false},{"nct_id":"NCT04204408","title":"A Research Study Investigating Mim8 in People With Haemophilia A","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06864481","title":"Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT06899789","title":"Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT06631326","title":"HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)","phase":"","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT03741881","title":"A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)","phase":"","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04340349","title":"Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":214,"lead_sponsor_name":"Instituto Nacional de Rehabilitacion","has_results":false},{"nct_id":"NCT07405216","title":"Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Centenario Hospital Miguel Hidalgo","has_results":false},{"nct_id":"NCT06353087","title":"Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Pfizer","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}